ProfileGDS5678 / 1415731_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 75% 75% 75% 74% 76% 76% 76% 77% 75% 74% 75% 76% 75% 75% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.8864175
GSM967853U87-EV human glioblastoma xenograft - Control 24.9995375
GSM967854U87-EV human glioblastoma xenograft - Control 34.9050375
GSM967855U87-EV human glioblastoma xenograft - Control 44.9482174
GSM967856U87-EV human glioblastoma xenograft - Control 55.0712876
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.9991676
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.9922876
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.2518977
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.9890675
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.9088474
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.9825375
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.1310976
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.9857175
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.0099975